BackgroundMicrosatellites are an adverse prognostic feature in melanoma that upstages node-negative disease to N1c in the AJCC 8th edition staging system. While Breslow thickness and microsatellites are established prognostic markers, their relationship in primary cutaneous melanoma has not been well examined.Materials and MethodsWe conducted a single-institution retrospective review of an IRB-approved prospective database of patients with primary cutaneous melanoma (January 2016-January 2026), excluding those with metastatic disease at diagnosis. Microsatellites are microscopic foci of melanoma cells discontinuous from the primary tumor and located in the dermis, subcutis, separated from the main tumor by normal tissue with no fibrosis or inflammation. Breslow thickness was measured from the granular layer (or the base of ulceration) to the deepest invasive melanoma cell. Patients were grouped by Breslow-based T-stage, and microsatellite frequency was calculated for each group. Fisher's exact test evaluated the association between T-stage and microsatellite presence.ResultsAmong 1,904 patients, 87 (4.6%) had microsatellites, with one patient having two separate microsatellite-positive tumors. Microsatellite frequency increased progressively with T-stage: 0.1% of T1 tumors (1/924), 2.4% of T2 tumors (14/579), 9.1% of T3 tumors (28/309), and 17.8% of T4 tumors (45/253) (Fisher's exact p<0.0001). Within the microsatellite-positive cohort, T-stage distribution was 1.1% for T1, 15.9% for T2, 31.8% for T3, and 51.1% for T4.DiscussionWe found that microsatellite frequency increases with Breslow thickness. Since microsatellites upstage tumors to N1c with implications for immunotherapy decisions, surgeons and dermatopathologists must be diligent in performing and assessing oncology wide excision specimens.
Saravanan et al. (Tue,) studied this question.